New drug RC88 shows promise for advanced cancers in early trial
NCT ID NCT05508334
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- RC88 (an injectable drug)
- What this could lead to
- If successful, RC88 could offer a new treatment option for people with advanced solid tumours who have not responded to standard therapies.
- What could go wrong
- This is an early-phase study with only 41 participants, so results may not apply to everyone. The main goal is safety, not yet proving effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
41 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. All subjects must be ≥ 18 years at the first screening examination / visit. 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. 3. Life expectancy of at least 12 weeks 4. Phase I must be histologically or cytologically confirmed and have failed standard therapy (disease progression after treatment) or are intolerant,unable to receive, or nonexistent to standard care,Patients with partial,advanced or metastatic malignant solid tumors; 5. Phase II-Advanced malignant solid tumor with MSLN expression 6. Patients with malignant pleural mesothelioma were assessed using mRECIST criteria, and those with other cancers were assessed using RECIST V1.1 criteria 7. Phase II-Mesothelin (MSLN) positive as confirmed by the central laboratory. 8. Adequate organ function 9. Voluntarily sign an informed consent form Exclusion Criteria: 1. Cancer metastases in the brain 2. Active infection or past hepatitis B or C infection 3. Major surgery less than 1 month before the start of the study 4. Uncontrolled heart disease 5. History of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies related compounds
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Remegen
Beijing, Beijing Municipality, China
-
Remgenen
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
- Custom-Built immune cells take aim at a notorious cancer mutation
- Experimental injection SHR-7787 put to the test against advanced solid tumors
- Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
- Can a pill shrink Hard-to-Treat ovarian tumors?
- Oral drug RVU120 put to the test against advanced solid tumors